Lantheus Holdings Inc. has completed the sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. The transaction includes the transfer of diagnostic agents such as TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®, as well as the portion of the North Billerica, Massachusetts campus dedicated to SPECT product manufacturing and related Canadian operations. Following this divestiture, Lantheus will focus on its commercial portfolio of PET radiodiagnostics, microbubbles, and advancing its radiopharmaceutical pipeline.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9618904-en) on January 02, 2026, and is solely responsible for the information contained therein.
Comments